Novavax, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Charles Jacobs
- Full Time Employees
- 749
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 Firstfield Road Gaithersburg MD United States of America 20878
- IPO Date
- Dec 5, 1995
- CIK
- 0001000694
- Website
- novavax.com
- Similar Companies
- Business
- Novavax, Inc., a biotechnology enterprise, dedicates itself to the research, advancement, and market introduction of vaccines aimed at preventing significant infectious illnesses. The company's lead commercial offering, Nuvaxovid, is a protein-based COVID-19 vaccine, which has secured full regulatory approval in the U.S. for adults aged 65 and older, as well as individuals 12 to 64 years old with specific elevated risk factors, providing a non-mRNA alternative. Its pipeline relies on a proprietary recombinant nanoparticle technology and the Matrix-M adjuvant. Important investigational programs feature a COVID-19-Influenza Combination vaccine and a standalone seasonal influenza vaccine, both advancing through Phase 3 clinical trials. Furthermore, a respiratory syncytial virus (RSV) F protein nanoparticle vaccine candidate remains under development. The company actively engages in strategic alliances, including a significant collaboration with Sanofi for the co-commercialization of Nuvaxovid and joint development of combination vaccines, and a partnership with Takeda for its COVID-19 vaccine in Japan. Novavax, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.
Company News
Novavax to Participate in September Investor Conferences
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?
Novavax Stock Climbs Monday: What's Going On?
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
US FDA approves updated COVID vaccines for 2026-27 season
Novavax Stock Pulls Back After Milestone Vaccine Success
Gold Mining, Drug Stocks Breaking Out Today
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax Q2 Earnings Call Highlights
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
Are Medical Stocks Lagging Novavax (NVAX) This Year?
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax: The Beaten-Down COVID-19 Darling
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know